Brief: Knight Therapeutics Announces Regulatory Supplemental Submission Of Minjuvi® (Tafasitamab) For Follicular Lymphoma In Argentina And Mexico
17/03/2026 11:42
March 17 (Reuters) - Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS ANNOUNCES REGULATORY SUPPLEMENTAL SUBMISSION OF MINJUVI® (TAFASITAMAB) FOR FOLLICULAR LYMPHOMA IN ARGENTINA AND MEXICO Source text: ID:nGNX2FX71k Further company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler